EBOS Group Ltd
NZX:EBO
Intrinsic Value
EBOS Group Ltd. engages in the provision of healthcare and animal care products and services. [ Read More ]
The intrinsic value of one EBO stock under the Base Case scenario is 57.88 NZD. Compared to the current market price of 35.45 NZD, EBOS Group Ltd is Undervalued by 39%.
Valuation Backtest
EBOS Group Ltd
Run backtest to discover the historical profit from buying and selling EBO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
EBOS Group Ltd
Current Assets | 3.3B |
Cash & Short-Term Investments | 365.3m |
Receivables | 1.5B |
Other Current Assets | 1.4B |
Non-Current Assets | 3.6B |
Long-Term Investments | 75.9m |
PP&E | 781.5m |
Intangibles | 2.6B |
Other Non-Current Assets | 225.8m |
Current Liabilities | 2.7B |
Accounts Payable | 2.3B |
Accrued Liabilities | 70.3m |
Other Current Liabilities | 242.3m |
Non-Current Liabilities | 1.9B |
Long-Term Debt | 1.6B |
Other Non-Current Liabilities | 309.9m |
Earnings Waterfall
EBOS Group Ltd
Revenue
|
12.7B
AUD
|
Cost of Revenue
|
-11.1B
AUD
|
Gross Profit
|
1.6B
AUD
|
Operating Expenses
|
-1.1B
AUD
|
Operating Income
|
464.6m
AUD
|
Other Expenses
|
-207.2m
AUD
|
Net Income
|
257.4m
AUD
|
Free Cash Flow Analysis
EBOS Group Ltd
EBO Profitability Score
Profitability Due Diligence
EBOS Group Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
EBOS Group Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
EBO Solvency Score
Solvency Due Diligence
EBOS Group Ltd's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
EBOS Group Ltd's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EBO Price Targets Summary
EBOS Group Ltd
According to Wall Street analysts, the average 1-year price target for EBO is 39.74 NZD with a low forecast of 35.33 NZD and a high forecast of 43.62 NZD.
Shareholder Return
EBO Price
EBOS Group Ltd
Average Annual Return | 23.86% |
Standard Deviation of Annual Returns | 17.87% |
Max Drawdown | -27% |
Market Capitalization | 6.8B NZD |
Shares Outstanding | 193 228 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
EBOS Group Ltd. engages in the provision of healthcare and animal care products and services. The firm is also an animal care products marketer and distributor. Its segments include Healthcare, Animal care and Corporate. The Healthcare segment incorporates the sale of healthcare products in a range of sectors, own brands, retail healthcare, wholesale activities and logistics. The Animal care segment incorporates the sale of animal care products in a range of sectors, own brands, retail and wholesale activities. Its businesses include Community Pharmacy, Institutional Healthcare, Contract Logistics and Animal Care. Community Pharmacy includes Symbion, Endeavour Consumer Health, ProPharma, DoseAid and Intellipharm. Institutional Healthcare includes EBOS Healthcare, Onelink, Clinect and Zest. Contract Logistics comprises Healthcare Logistics, Symbion Contract Logistics and Symbion Clinical Trials. Animal Care includes Masterpet, Lyppard, Animates and Vitapet.
Contact
IPO
Employees
Officers
The intrinsic value of one EBO stock under the Base Case scenario is 57.88 NZD.
Compared to the current market price of 35.45 NZD, EBOS Group Ltd is Undervalued by 39%.